New drug combo aims to tame Tough-to-Treat blood cancer
NCT ID NCT07409428
Summary
This study is testing if adding an experimental drug called HMPL-760 to a standard chemotherapy regimen (R-GemOx) works better than the chemotherapy alone for patients with an aggressive type of lymphoma that has returned or not responded to prior treatment. About 240 adults with this condition will be randomly assigned to receive either the new combination or the standard treatment plus a placebo. The main goals are to see if the new combination helps keep the cancer from progressing longer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.